where are you cavalabs?, page-24

I agree with you.  I don’t think it’s MGC’s neglect- it’s Cavalabs

For all we know MGC issued a cease and assist to CV when they used advertised formulated by MGC then did not sell the products.

No CBD products have been for sale on Cavalabs site for a month.  An email I received from CV said the MGC line will be out mid year.  They will

Ultimately the CV deal is a drop in the pond compared to what MGC can do.   The $40mil is nice, but, even without the CV deal this stock is so undervalued

It seems to me every time there’s good news, the CV deal is brought up.  Stop beating a dead horse- if you don’t trust management sell me your shares.

Cannepil at $1mil per 100 patients is the $$$$ Market here- MGC only owns 50% of Derma ($20mil to them).  I’d guess they can grab 2000 patients out of the 1,270,000 in Europe and Australia to make up that $20mil if the CV deal tanks (I think a purple pig would fly through my house before that happens)

GW Pharma is basically giving Cannepil free marketing as its world wide news pending FDA approval for their treatment for Epilepsy in children